A Multi-center, Randomized, Double-Masked, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Licaminlimab for the Treatment of Dry Eye Disease
Latest Information Update: 12 May 2025
At a glance
- Drugs Licaminlimab (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Acronyms RELIEF
- Sponsors Oculis Pharma
Most Recent Events
- 01 May 2025 According to an Oculis Pharma media release, According to an Oculis Pharma media release, data from this study will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
- 20 Jan 2025 Status changed from active, no longer recruiting to completed.
- 07 Nov 2024 According to an Oculis media release, Company is planning to consult with the FDA in Q1 2025 to discuss the positive topline results from the Phase 2b RELIEF trial and next steps for OCS-02 (licaminlimab) development.